Previous 10 | Next 10 |
Gainers: Creative Realities (NASDAQ: CREX ) +125% . More news on: Creative Realities, Inc., Syndax Pharmaceuticals, Inc., Kura Oncology, Inc., Stocks on the move, , Read more ...
Broadwind Energy (NASDAQ: BWEN ) +60% . on $19M order . More news on: Broadwind Energy, Inc., TrovaGene, Inc., SmileDirectClub, Inc., Stocks on the move, , Read more ...
Syndax Pharmaceuticals (NASDAQ: SNDX ) is up 21.6% after hours following some early data on its menin-inhibitor leukemia drug SNDX-5613. More news on: Syndax Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Gainers: RTIX +50.0% . QTNT +19.6% . SNDX +17.3% . PI +9.2% . More news on: RTI Surgical Holdings, Inc., Quotient Limited, Syndax Pharmaceuticals, Inc., Stocks on the move, , Read more ...
WALTHAM, Mass. , April 27, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today presents preclinical and initial clinical data for SNDX-56...
WALTHAM, Mass. , April 14, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced three presentations at the upcoming 2020 America...
WALTHAM, Mass. , Feb. 25, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its fourth quarter and ...
WALTHAM, Mass. , Feb. 18, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will particip...
Syndax Pharmaceuticals (NASDAQ: SNDX ) has entered into an agreement with five leading life sciences investors, for the purchase of common stock at $8.00 per share, for expected gross proceeds of ~$35M. More news on: Syndax Pharmaceuticals, Inc., Hercules Capital, Inc., Healthcare stocks...
WALTHAM, Mass. , Jan. 31, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it has entered into an agreement with fi...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
14.37%Change Percent:
Syndax Pharmaceuticals Inc. Company Name:
SNDX Stock Symbol:
NASDAQ Market:
Syndax Pharmaceuticals Inc. Website:
Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia PR Newswire – New PDUFA action date of December 26, 2024 allows FDA additional time to complete their review – WALTHAM, Mass. , ...
Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024 PR Newswire WALTHAM, Mass. , July 25, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing...
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by the rapid growth of abnormal myeloid cells, which are immature blood cells that normally...